MindMaze Therapeutics culls program, ends legacy ops from Relief merger to cut costs

Digital therapeutics specialist MindMaze Therapeutics is selling off a pipeline program whilst also removing all non-neurology legacy operations from its recent merger with Relief Therapeutics. Digital therapeutics specialist MindMaze Therapeutics is selling off a pipeline program whilst also removing all non-neurology legacy operations from its recent merger with Relief Therapeutics. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources…

Source: FierceBiotech